Skip to content
Open access · OA via OpenAlex

Can removal of zombie cells revitalize the aging cardiovascular system?

Seyed Soheil Saeedi Saravi, Mark W. Feinberg

European Heart Journal · 2024 · ▲ 8 citations

Abstract

Aging poses a burgeoning challenge in the modern world, as increasing life expectancies and shifting demographics contribute to a growing elderly population. In the intricate drama of aging, senescent cells (SNCs) play a chilling role akin to ‘zombie cells’ in horror movies. They refuse to die, instead wreaking havoc by secreting detrimental substances that can harm neighbouring cells. Their persistent presence, much like relentless zombies, leads to a decline in tissue function and is closely associated with various age-related diseases.1 As age advances, SNCs accumulate in our body organs comprising the cardiovascular system. Notably, these cells stimulate pro-survival pathways and hinder their regenerative capacity. Given the limited proliferative potential of cardiomyocytes and vascular endothelial cells, the accumulation of these SNCs accelerates the deterioration of cardiovascular regeneration. This issue is exacerbated by the fact that cardiovascular diseases (CVD) manifest a significant health concern among the aging population. Cellular senescence(definition) can be triggered by a myriad of factors, including chronic oxidative stress, telomere(definition) attrition, DNA instability, and metabolic imbalances.2 Moreover, specific secretomes can induce senescence through the activation of the senescence-associated secretory phenotype (SASP), leading to a chronic inflammatory microenvironment. Disrupted signalling pathways, such as the p16INK4a-p19INK4d and p53-p21WAF1/Cip1 pathways and the mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) that promote proliferative arrest, play pivotal roles in mediating senescence in the cardiovascular system.3 For instance, artificial removal of p16INK4a-expressing SNCs from INK-ATTAC transgenic mice or Ldlr−/−;3MR mice delayed aging-related phenotypes, including cardiac arrhythmias, arterial stiffening, and atherosclerosis.2,4 Recognition of senescence hallmarks has spurred investigations into genetic and pharmacological interventions targeting key pathways, including the SASP and apoptosis, in an effort to preserve cardiovascular health and extend lifespan. Pharmacological senotherapies primarily fall into two categories: senolytics(definition), which differentially eliminate SNCs, and senomorphics, which neutralize the detrimental SASP to induce senostasis5 (Figure 1). These therapies show promise in mitigating age-related cardiovascular impairments. Nonetheless, it is crucial to execute senostasis or SNC removal with caution, as injury-induced senescence at a transient state, but not a prolonged state, positively influences the reparative milieu of the heart and vasculature. Cardiovascular senescent cell features targeted by senolytics and senomorphics. Schematic illustration of cellular senescence hallmarks in the aging cardiovascular system. Multiple drivers of cellular senescence activate pro-survival senescent cell anti-apoptotic pathway networks while stimulating cell cycle arrest signals. Senolytics are employed to target senescent cell anti-apoptotic pathway and other survival networks, as well as proliferative arrest pathways, effectively eliminating cardiovascular senescent cells. Senomorphic compounds target pathological senescence-associated secretory phenotype signalling, either preventing the production or neutralizing senescence-associated secretory phenotype components in senescent cells (images created with BioRender.com) The application of senolytics for cardiovascular rejuvenation emerged as a revolutionary concept in the early 21st century. This therapeutic approach has exhibited promise in various preclinical studies, offering hope for potential revitalizing cardiovascular system in aging. Recent discoveries propose a number of mechanistic nodes for senolytics that potentially alleviate chronic cardiovascular conditions such as atherosclerosis, cardiac fibrosis, and hypertension. The majority of senolytics identified to date selectively eliminate SNCs by disrupting senescent cell anti-apoptotic pathway (SCAP) pro-survival pathways such as p53-p21WAF1/Cip1 and BCL-2 family proteins, which are upregulated in SNCs.3 The heterogeneity in senolysis at the single-cell level among various types of SNCs has prompted researchers to explore specific senolytics that function effectively in the aging cardiovascular system.4 The first reported senolytic was a combination of dasatinib (D), an FDA-approved anti-cancer drug, and quercetin (Q), a natural flavonoid, that targets SCAP, including BCL-2, p21WAF1/Cip1, and PI3K.5 In a mouse model of atherosclerosis, D + Q reduced plaque burden and improved vascular function by selectively eliminating SNCs from atherosclerotic lesions.6 Additionally, D + C improved age-related cardiac dysfunction by rescuing endothelial senescence-induced denervation in aged mice.7 In patients with heart failure with preserved ejection fraction (HFpEF), the most common form of HF in the elderly, D + Q improved cardiac function and exercise capacity.6 Subsequent research has explored additional compounds with similar properties, including BCL-2 family inhibitors, HSP90 inhibitors, p53 pathway–targeting compounds (such as FOXO4-p53, MDM2/p53, or USP7 inhibitors), and natural products for clearing SNCs.3 However, not all of these compounds have been tested for their senolytic effects in the cardiovascular system. Among them, navitoclax, a BCL-2 family inhibitor, FOXO4-DRI, a FOXO4-p53–targeting peptide, and fisetin, an herbal flavonoid, have demonstrated potential as senolytic agents in preclinical models of heart failure with reduced ejection fraction (HFrEF), myocardial infarction, and atherosclerosis.4,6 While senolytics hold promise in ameliorating aging-associated diseases (AAD), the challenges lie in identifying senescence biomarkers and their off-target effects. Researchers are now looking into developing second-generation senolytics to more selectively target SNCs.8 One biomarker considered as the gold standard in detecting cellular senescence is the lyso

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/eurheartj/ehad849
Canonical
link ↗
Fetched
2026-11-02 MST

Cite this

APA
Saravi, S.S.S., &amp; Feinberg, M.W. (2024). Can removal of zombie cells revitalize the aging cardiovascular system?. <em>European Heart Journal</em>. https://doi.org/10.1093/eurheartj/ehad849
Vancouver
Saravi SSS, Feinberg MW. Can removal of zombie cells revitalize the aging cardiovascular system?. European Heart Journal. 2024. doi:10.1093/eurheartj/ehad849.
BibTeX
@article{seyed2024Canrem, title = {Can removal of zombie cells revitalize the aging cardiovascular system?}, author = {Seyed Soheil Saeedi Saravi and Mark W. Feinberg}, journal = {European Heart Journal}, year = {2024}, doi = {10.1093/eurheartj/ehad849}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings